Development of vaccines for Marburg hemorrhagic fever

Daniel G. Bausch, Thomas Geisbert

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.

Original languageEnglish (US)
Pages (from-to)57-74
Number of pages18
JournalExpert Review of Vaccines
Volume6
Issue number1
DOIs
StatePublished - Feb 2007
Externally publishedYes

    Fingerprint

Keywords

  • Filoviridae
  • Filovirus
  • Marburg hemorrhagic fever
  • Marburg virus
  • Pathogenesis
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this